New discoveries. Challenging cases. Conversations that move GU oncology forward.

Join us at MaTOS-GU 2027, where leading experts will explore molecular testing, immunotherapy, targeted therapies, and emerging clinical trials—connecting the latest evidence with decisions in ng your questions, share your perspective, and connect with colleagues shaping the future of GU cancer care.

📅 March 18–21, 2027
📍 The Ritz-Carlton Dove Mountain | Tucson, Arizona

🔗 Register today at matos-gu.com

#MaTOSGU #GUOncology #GenitourinaryCancer #OncologyEducation #Immunotherapy #PrecisionOncology

@drulkav
@HHAMMERSMD
@ADESAIONCMD
@JenniferKingMD
@tomjayram
@umangtalking
@arnabguonc
@AmandaNizamMD
@katy_beckermann
@oncoBellmunt
@drkarinetawagi
@sonpavde
@BraunMDPhD
@jgong15
@drjefstathiou
@h_alahmadie
@YLeyfman
@walterstadler5
@bogdanaschmidt
@DrOmarMian
@MikeLattanzi
@ZakhariaYousef
@bergsa83
@KalantriShreyas
@fedghali
@rohitjainMD
@AtishChoudhury
@JasonBrownMDPhD
@YuWeiChenMD

Another impressive slate of candidates, but my vote goes to my dear friend Petros Grivas! A brilliant oncologist, tireless advocate for patients. ASCO would be fortunate to have him on the Nominating Committee!

Voting is now open! Cast your vote at asco.org/about-asco/asc…

Beyond their stellar scientific work, @montypal and @PGrivasMDPhD stand out for their incredible human warmth and ability to build bridges for global oncology collaboration. Always supportive of @urologysummit and the next generation!
Please support them in the #ASCO elections!

Excited to see my friend @PGrivasMDPhD running for the ASCO Nominating Committee! Petros brings dedication, generosity, and a deep commitment to our oncology community. He has my enthusiastic support - please consider giving him yours! @tompowles1 @brian_rini @neerajaiims

@ASCO elections are open now until Dec 2nd!
This year proud to support friends @montypal @PGrivasMDPhD @wandering_gu Todd Morgan @AshleySumrallMD -- and @teekayowo for President Elect!
Vote for ASCO asco.org/election
@OncoAlert @WomeninOnc

Absolutely no surprise here! 🎉👏 So well deserved @brian_rini & @tompowles1
A huge fan of @Uromigos and the brilliant Tom and Brian❤️ Their passion, wit, and ability to bring the global GU oncology community together for insightful, engaging, and entertaining conversations make thisand unique with a 🌏 footprint!

Congratulations on this wonderful recognition! 🎙️🏆
@LosUromigos @uromigosjapan @OncoAlert @montypal @neerajaiims @Silke_Gillessen @PGrivasMDPhD @DrChoueiri @ChrisSweens1 @kalasri3
@myESMO @UroDocAsh

Please vote

@montypal w phase 1 data from XmAb819 ENPP3/CD3 bispecific in tx-refractory #kidneycancer — manageable CRS & promising responses dose dependent. ENPP3 very interesting target for RCC.
@OncoAlert #ESMO26 @myESMO

ENPP3 x CD3 ! Seismic Shift to come !!

Let’s end using non IO drugs in the frontline and focus on CURE!

✨✨Hope alert: @sands_jacob shows that adding tarla to durva for maintenance therapy significantly improves survival to 21.1mo!

Followed by a masterful discussion by @StephenVLiu integrating clinical outcomes including tox, translational thoughts, and accessibility!
"We cannot the delivery of our care be our legacy"

#ESMO26 @OncoAlert

PROTEUS substudy at #ESMO26 presented by Alberto Briganti 🇪🇸

Perioperative apalutamide + ADT vs RP + PLND alone in HR localized/LA prostate cancer (N=408, 1:3)

▪️ EFS HR 0.38 (0.26–0.55), p<0.0001
▪️ 36-mo EFS 63% vs 41%; SOC median EFS only 19.1 mo
▪️ Benefit held after T recChoueiri @DrRanaMcKay @tompowles1 #ProstateCancer

With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.

⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.

#BladderCancer #GUOnc @OncoAlert @BladderCancerUS

PEACE-1 at 7.7 years, de novo mCSPC: abiraterone added to ADT plus docetaxel with long term improves survival.

📈 Docetaxel population, n=710: OS HR 0.68, median 6.2 vs 4.4 years, 7-year OS 45.7% vs 30.7%
📊 OS HR was 0.75 at the 2022 analysis, so the effect grew with follow-up
n ARPI after progression. No long-term safety signal

Fizazi's point this investigator imitated trial gives us what few industry frontline trials by following patients this long.

#ESMO26 #ProstateCancer #mCSPC #GUonc

PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday #ESMO26

Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306)
🚨EFS: HR 0.38, 95% CI 0.26–0.55
🚨MFS: HR 0.49, 95% CI 0.26–0.90
🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
🚨All Gr Hot Flush: 64% vs 0.7%

Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!

IO + EV upfront is now the SoC for MIBC!! But how much EV do we need in postOP settings? Eagerly looking forward to more data/discussion on Day 2 #ESMO26! VOLGA as the new SoC!!??!!

#gusm @myESMO #BladderCancer

🚨 Perioperative immunotherapy in MIBC at #ESMO2026. Three phase III trials, three different answers, and one uncomfortable lesson for those of us who report pCR. 🔬

📊 NIAGARA (durvalumab + GC, n=1,063): pCR 37.3%, EFS HR 0.68 (0.56–0.82), OS HR 0.75 (0.59–0.95) ✅

📊 mab + GC, n=907): pCR 44.4%, EFS HR 0.88 (0.71–1.10), OS HR 1.00 (0.76–1.27) ❌

📊 CA017-078 (nivolumab + GC, n=653): pCR 39.1%, EFS HR 0.94 (0.71–1.25), OS HR 0.88 (0.64–1.21), OS immature ❌

Cross-trial, not head to head. Populations, schedules, follow-up (34 to 55 months) and statistical design all differ, so the ranking is exploratory.
But look at the direction. The trial with the highest pCR returned an OS hazard ratio of exactly 1.00. 🧠
Three points from the pathology side:
1️⃣ pCR is a response marker, not a surrogate. Comparable absolute pCR gains of roughly 9 to 10 points across all three, divergent survival. If pCR tracked cure, that pattern should not be possible. pCR remains elusive at least for standard chemotherapy plus IO.
2. And pCR itself is not standardised across trials. ypT0N0 depends on sampling protocol, block numbers, regression assessment and whether review is central or local. The NIAGARA figure quoted here comes from a reanalysis, which tells you the endpoint moved on re-review. A 9-point difference is not comfortably above that measurement noise.
Also worth noting: NIAGARA and KEYNOTE-866 both gave adjuvant IO, CA017-078 did not. So adjuvant continuation alone does not explain the split either. We genuinely do not know why these diverged. 🎯
Which is the real message. We are comparing trials on an endpoint we produce, that is not validated, not standardised, and not stratified by biology. Fixing that is a pathology job, and it is overdue. We need that now more than ever with neoadjuvant systemic phase becoming SOC.
@OncoAlert @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot
#Uropathology #BladderCancer #blcsm #MIBC #pathtwitter
Great summary below from Niklas Klümper.

Important data from #ESMO2026 in #mCRPC:

🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH).

⚠️ Patients with CH-only HRR alterations did not appear to benefit from PARPi monotherapy.

Distinguishing CH from is critical for treatment selection. #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert

✈️ En route to Madrid for #ESMO26, landing just in time for the data to start Friday morning. Most excited for: VOLGA LBA2 in bladder cancer, INTerpath-001's first phase 3 neoantigen win, LITESPARK-011 final in kidney cancer, and DASL-HiCaP in prostate. What a week ahead 🔬 #GUonc

Fantastic @VickersBiostats double-header @UCSanDiego this week

To @UCSDRadMed trainees: Statistical slip-ups to avoid (plus bonus chat after on tips for success in academics)

To @UCSDCancer GU team: quantitative Gleason pattern 4

Engaging, interesting, provocative🙏🏼 👏🏼👏🏼